ArthroCare Corp. (ARTC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ArthroCare Corp. (ARTC) trades at $0.53 with AI Score 44/100 (Grade C). ArthroCare Corp. specializes in developing and marketing minimally invasive surgical devices, primarily focused on soft tissue repair. Market cap: $16.13M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for ARTC: ARTC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARTC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ARTC: the 1 perspectives are evenly split.
How is this calculated? →ArthroCare Corp. (ARTC) Healthcare & Pipeline Overview
ArthroCare Corp. develops and markets minimally invasive surgical devices for soft tissue repair, holding a position in the arthroscopic surgery market. Their focus on innovative technologies and physician training aims to improve surgical outcomes and efficiency, differentiating them in the competitive medical device landscape.
What Is the Investment Thesis for ARTC?
ArthroCare Corp.'s investment thesis hinges on its innovative Coblation technology and its application in minimally invasive surgical procedures. The company's focus on soft tissue repair in sports medicine, spine, and ENT markets positions it within high-growth segments of the medical device industry. Key value drivers include the continued adoption of minimally invasive techniques, the expansion of ArthroCare's product portfolio, and its ability to secure favorable reimbursement rates for its procedures. However, potential risks include increased competition from established medical device companies, regulatory challenges, and the need for ongoing innovation to maintain its technological edge. The company's beta of 1.47 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
ARTC Key Highlights
- ArthroCare's core technology, Coblation, offers a unique approach to soft tissue removal and modification during surgery.
- The company's focus on minimally invasive procedures aligns with the growing trend towards less invasive surgical techniques.
- ArthroCare's product portfolio addresses a range of conditions in sports medicine, spine, and ENT markets.
- The company's business model involves direct sales to hospitals and surgery centers, as well as surgeon training and support.
- ArthroCare's global reach extends through strategic partnerships and acquisitions.
Who Are ARTC's Competitors?
ARTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| BSX Boston Scientific Corporation | $44.60 | -1.20% | 67B | 82 |
| MDT Medtronic plc | $83.35 | +0.19% | 107B | 77 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARTC's Key Strengths?
- Proprietary Coblation technology
- Focus on minimally invasive procedures
- Strong relationships with surgeons
- Established presence in key markets
What Are ARTC's Weaknesses?
- Reliance on a single core technology
- Smaller size compared to major competitors
- Potential for product liability claims
- Dependence on reimbursement rates
What Could Drive ARTC Stock Higher?
- Continued adoption of minimally invasive surgical techniques.
- Expansion of ArthroCare's product portfolio.
- Strategic partnerships and acquisitions.
- Potential regulatory approvals for new products.
What Are the Key Risks for ARTC?
- Increased competition from established medical device companies.
- Regulatory challenges and changes in reimbursement rates.
- Product liability claims.
- Dependence on surgeon adoption of Coblation technology.
What Are the Growth Opportunities for ARTC?
- Expansion into Emerging Markets: ArthroCare Corp. has the opportunity to expand its presence in emerging markets, where demand for advanced medical technologies is growing rapidly. These markets offer significant potential for revenue growth, as healthcare systems in these regions invest in modernizing their infrastructure and improving patient care. The timeline for realizing this growth opportunity is estimated to be within the next 3-5 years, with a potential market size of several billion dollars.
- Development of New Applications for Coblation Technology: ArthroCare Corp. can leverage its core Coblation technology to develop new applications in other surgical specialties. This could involve adapting the technology for use in areas such as orthopedic surgery, cosmetic surgery, or general surgery. The development of new applications would expand ArthroCare's addressable market and create new revenue streams. This growth opportunity could materialize within the next 2-4 years, with a potential market size of hundreds of millions of dollars.
- Strategic Partnerships and Acquisitions: ArthroCare Corp. can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This could involve partnering with or acquiring companies that have complementary technologies or that operate in adjacent markets. Strategic partnerships and acquisitions can accelerate ArthroCare's growth and enhance its competitive position. Such initiatives could yield results within the next 1-3 years, depending on the specific opportunities pursued.
- Increased Focus on Surgeon Training and Education: ArthroCare Corp. can invest in expanding its surgeon training and education programs to drive adoption of its products and improve surgical outcomes. This could involve offering hands-on training courses, online educational resources, and peer-to-peer learning opportunities. By providing surgeons with the knowledge and skills they need to effectively use ArthroCare's technologies, the company can increase demand for its products and build stronger relationships with its customers. This ongoing effort can continuously improve market penetration.
- Development of Next-Generation Surgical Devices: ArthroCare Corp. can invest in research and development to create next-generation surgical devices that offer improved performance, ease of use, and patient outcomes. This could involve incorporating new materials, advanced sensors, and sophisticated software algorithms into its devices. The development of next-generation devices would allow ArthroCare to maintain its technological edge and capture a larger share of the market. This long-term strategy, with a 3-5 year horizon, is crucial for sustained growth.
What Opportunities Does ARTC Have?
- Expansion into emerging markets
- Development of new applications for Coblation technology
- Strategic partnerships and acquisitions
- Increased focus on surgeon training and education
What Threats Does ARTC Face?
- Competition from larger medical device companies
- Technological obsolescence
- Regulatory changes
- Economic downturns
What Are ARTC's Competitive Advantages?
- Proprietary Coblation technology
- Strong relationships with surgeons
- Focus on minimally invasive procedures
- Established presence in sports medicine, spine, and ENT markets
What Does ARTC Do?
ArthroCare Corp., headquartered in Sunnyvale, California, was a medical device company focused on developing, manufacturing, and marketing minimally invasive surgical products. The company's core technology, Coblation, utilized radiofrequency energy to precisely remove or modify soft tissue during arthroscopic procedures. ArthroCare's history is rooted in the development of innovative surgical solutions aimed at improving patient outcomes and reducing recovery times. The company's product portfolio included devices for sports medicine, spine, and ear, nose, and throat (ENT) procedures. These devices were used by surgeons to treat a variety of conditions, including rotator cuff tears, meniscus injuries, and spinal disc herniations. ArthroCare's business model revolved around selling its products directly to hospitals and surgery centers, as well as providing training and support to surgeons on the proper use of its technologies. The company also focused on expanding its global reach through strategic partnerships and acquisitions. ArthroCare was acquired, marking a significant shift in its operational structure and market presence.
What Products and Services Does ARTC Offer?
- Develops and markets minimally invasive surgical devices.
- Utilizes Coblation technology for soft tissue removal and modification.
- Offers products for sports medicine, spine, and ENT procedures.
- Provides solutions for rotator cuff tears, meniscus injuries, and spinal disc herniations.
- Sells products directly to hospitals and surgery centers.
- Offers training and support to surgeons.
How Does ARTC Make Money?
- Develops and manufactures minimally invasive surgical devices.
- Sells products directly to hospitals and surgery centers.
- Provides training and support to surgeons on the use of its technologies.
- Expands global reach through strategic partnerships and acquisitions.
What Industry Does ARTC Operate In?
ArthroCare Corp. operated within the medical instruments and supplies industry, a sector characterized by technological innovation, stringent regulatory requirements, and intense competition. The industry is driven by factors such as an aging population, increasing demand for minimally invasive procedures, and advancements in surgical techniques. ArthroCare competed with larger, more established medical device companies, as well as smaller, specialized players. The company's success depended on its ability to differentiate its products through technological innovation, clinical efficacy, and cost-effectiveness.
Who Are ARTC's Key Customers?
- Hospitals
- Surgery centers
- Surgeons specializing in sports medicine
- Surgeons specializing in spine surgery
- Surgeons specializing in ENT procedures
Company Profile
ArthroCare Corp. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Sunnyvale, US. ARTC has traded publicly since 2010.
ArthroCare Corp. (ARTC) Valuation Context
Valued at $16.13M, ARTC is classified as a micro-cap stock. Relative to its peer group, ARTC's quantitative score of 44/100 is below the peer average of 77/100.
ROE 0%Key Financial Metrics
Return on equity for ArthroCare Corp. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ARTC trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Net buyingInsider Activity
The most recent 12 insider filings for ArthroCare Corp. break down as 3 sales and 9 purchases. On net that is roughly 81K shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.
ARTC Financials
Bull Case vs Bear Case
Bull Case
- ArthroCare's recent insider buying suggests those in the know see long-term value, signaling confidence despite market headwinds.
- The buzz around ArthroCare within the community is noticeably positive, with many anticipating growth driven by their innovative medical devices.
- There's a growing perception that ArthroCare is undervalued, especially considering their potential in the expanding sports medicine market.
- Recent market developments indicate increased demand for minimally invasive surgical solutions, a space where ArthroCare excels, potentially boosting their market share.
Bear Case
- Despite positive sentiment, some community members are concerned about increasing competition in the arthroscopic surgery market.
- Recent insider selling activity, while less prominent than buying, raises questions about short-term profit-taking or potential internal concerns.
- Market perception suggests ArthroCare might face challenges in scaling production to meet growing demand, potentially impacting revenue.
- Bearish community views highlight potential regulatory hurdles for ArthroCare's new product lines, which could delay market entry and impact investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ARTC Latest News
No recent news available for ARTC.
ARTC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARTC.
Price Targets
Wall Street price target analysis for ARTC.
ARTC MoonshotScore
What does this score mean?
The MoonshotScore rates ARTC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ARTC Healthcare Stock FAQ
What does ArthroCare Corp. do?
ArthroCare Corp. was a medical device company that developed, manufactured, and marketed minimally invasive surgical devices. Its core technology, Coblation, used radiofrequency energy to precisely remove or modify soft tissue during arthroscopic procedures. The company's products were used in sports medicine, spine, and ENT procedures, offering surgeons solutions for conditions such as rotator cuff tears, meniscus injuries, and spinal disc herniations. ArthroCare's business model involved direct sales to hospitals and surgery centers, as well as providing training and support to surgeons.
What are the main risks for ARTC?
The main risks for ArthroCare Corp. include competition from larger medical device companies, technological obsolescence, regulatory changes, and economic downturns. The company's reliance on a single core technology, Coblation, exposes it to the risk of disruption from alternative technologies. Regulatory changes and changes in reimbursement rates could also negatively impact ArthroCare's financial performance. In addition, the company faces the risk of product liability claims, which could result in significant financial losses. Economic downturns could reduce demand for elective surgical procedures, impacting ArthroCare's sales.
How does ArthroCare Corp. navigate regulatory approval processes?
ArthroCare Corp. navigated regulatory approval processes by adhering to stringent quality control standards and conducting thorough clinical trials to demonstrate the safety and efficacy of its products. The company worked closely with regulatory agencies such as the FDA to ensure compliance with all applicable regulations. ArthroCare also invested in regulatory affairs expertise to stay abreast of changes in the regulatory landscape and to proactively address any potential issues. The company's regulatory strategy was critical to its ability to bring new products to market and maintain its competitive position.
How does ArthroCare Corp. manage patent expiration risks?
ArthroCare Corp. managed patent expiration risks by continuously innovating and developing new products and technologies to replace those that were losing patent protection. The company also pursued strategies such as extending the life of its existing patents through incremental improvements and securing new patents for related technologies. ArthroCare also actively monitored the competitive landscape to identify potential threats from biosimilar or generic products. The company's patent management strategy was essential to protecting its intellectual property and maintaining its market share.
What are the key factors to evaluate for ARTC?
ArthroCare Corp. (ARTC) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ARTC data refresh on this page?
ARTC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARTC's recent stock price performance?
ArthroCare Corp. (ARTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Coblation technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARTC overvalued or undervalued right now?
Valuing ArthroCare Corp. (ARTC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ARTC. Information is based on available data and may not be complete or up-to-date.